Chongqing Claruvis Pharmaceutical Co., Ltd. recently announced that the China's National Medical Products Administration (NMPA) has approved its Retoxin&...
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administra...
Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as "ATLATL"), global innovation platform for life science research and de...
-Illumia, formerly known as Transact + CBORD, an award-winning leader in innovative higher education, healthcare, senior living, and corporate technology...
Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Porton...
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manu...
"In the first quarter, Samsung Biologics delivered stable growth, supported by consistent execution across our manufacturing network and continued demand f...
Andelyn Biosciences, (“Andelyn”) a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (&ldqu...
ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), is approved for use in Australia and Singapore as a first-...
Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing indica...
This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipeline Under the terms of the agreement, Nxe...
NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development und...
DualityBio announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate ("ADC") trastuzumab pamirtecan ("T-Pam"...
NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced that it has entered into an exclusive dis...
© 2026 Biopharma Boardroom. All Rights Reserved.
